Cybersecurity Stocks: Netskope IPO Jumps In First Day Of Trading – Investor's Business Daily
RETIREMENT: Should You Take Social Security ASAP? 
In the second initial public offering for cybersecurity stocks in 2025, Netskope (NTSK) stock jumped on Thursday. Netskope stock trades on the Nasdaq composite.
In the Netskope IPO, the cybersecurity firm raised over $900 million with a valuation of $7.3 billion. Shares were priced at $19 at the open. On the stock market today, Netskope stock jumped 18% to 22.43 in midday trading.
Netskope operates a cloud-based Secure Access Service Edge, or SASE, platform that supports remote workers and branch offices. Founded in 2012, Netskope competes against Palo Alto Networks (PANW), Zscaler (ZS) and many others.
According to a Netskope regulatory filing, the company’s revenue increased 31% year-over-year to $328 million for the six months ended July 31. It had a net loss of $170 million, improving from a $207 million loss a year earlier.
“Through the Netskope One platform, we bring advanced security right to the edge via our lightning-fast global private cloud,” said cofounder and Chief Executive Sanjay Beri in the filing. “We designed it to understand the new ‘language’ of this modern internet, to leverage AI for superior insight and control over every digital interaction, whether from a user, a device, an app, or an AI agent, and to safeguard data and organizations against both threats and data leaks, in real time.”
Netskope has focused on the financial services, health care and federal government markets.
SailPoint (SAIL), backed by private equity firm Thoma Bravo, launched an IPO in February. SailPoint stock has dipped about 2% in 2025.
IBD’s group of cybersecurity stocks ranks No. 117 out of 197 groups tracked.
Follow Reinhardt Krause on X, formerly Twitter, @reinhardtk_tech for updates on artificial intelligence, cybersecurity and cloud computing.
YOU MAY ALSO LIKE:
CrowdStrike Jumps After Guiding Key Growth Metric Above Views
Learn The Best Trading Stock Rules From IBD’s Investor’s Corner
Want To Trade Options? Try Out These Strategies
Monitor IBD’s “Breaking Out Today” List For Companies Hitting New Buy Points
IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today
9/16/2025 In the second IPO for cybersecurity stocks in 2025, Netskope raised its proposed price range to 17 to 19. Netskope…
9/16/2025 In the second IPO for cybersecurity stocks in 2025, Netskope…
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.
*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.
IBD, IBD Digital, IBD Live, IBD Weekly, Investor’s Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor’s Business Daily, LLC.
©2025 Investor’s Business Daily, LLC. All Rights Reserved.
source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.
